News

Matthew Ingham, MD, discusses some of the most recent clinical updates in the sarcoma space.

Following positive data from the phase 1 ReSPECT-GBM trial, the first patient has been dosed with rhenium (186Re) obisbemeda in the phase 2 portion.

In an interview with Targeted Oncology, Thomas Flaig, MD, further discussed the updates to the 2022 NCCN guidelines for patients with bladder cancer and explained how the field has evolved over the past few years.

In an interview with Targeted Oncology, Melanie Goldfarb, MD, MSc, FACS, FACE, highlighted the importance of long-term survivorship care and the quality-of-life aspects of patients with thyroid cancer.

A speedy FDA review of the approval application for avapritinib for indolent systemic mastocytosis has commenced.

An investigational new drug application for IMPT-314 has been cleared by the FDA. A phase 1/2 trial investigating the agent will be initiated in early 2023.

Thomas Flaig, MD, discusses some of the updated and current NCCN guidelines for patients with bladder cancer.

Cyrus M. Khan, MD, discusses the mechanism of action of glofitamab and its potential use as a treatment option for patients with relapsed/refractory large B-cell lymphoma.

In an interview with Targeted Oncology, Tanios Bekaii-Saab, MD, FACP, discussed the methods and design of the MOUNTAINEER-03 trial and its role following the positive data observed from MOUNTAINEER.

Breast and gastric cancer algorithms are acceptable to use when identifying patients with colorectal cancer who may respond to tucatinib in combination with trastuzumab.

Findings from the phase 3 NAPOLI 3 trial support the NALIRIFOX regimen as a first-line treatment for patients with metastatic pancreatic ductal adenocarcinoma.

Rachel Würstlein, MD, discusses the use of trastuzumab emtansine following the KAMILLA trial which evaluated the agent in patients with HER2-positive locally advanced or metastatic breast cancer who have brain metastases.

After the FDA cleared an investigational new drug application for mocravimod in April 2022, the first patients with acute myeloid leukemia undergoing allogeneic hematopoietic cell transplant have been enrolled in a phase 2b/3 study of the agent.

Although the need for novel approaches to treat patients with TP53-mutated acute myeloid leukemia remains urgent, cautious optimism may be in order given recent data from clinical trials and upcoming studies.

In a presentation delivered at the 2022 Large Urology Group Practice Association Annual Meeting, Evan Y. Yu, MD, discussed different sequencing strategies that can be utilized for patients with mCRPC and the data that support each approach.

Due to its potential to fill a treatment gap in the HER-low and HER-positive endometrial cancer space, DB-1303 now has an FDA fast track designation.

Treatment with tisagenlecleucel in patients with relapsed/refractory B-cell acute lymphoblastic leukemia led to a 79% morphologic complete response rate.

SWOG 1815, which was investigating nab-paclitaxel plus gemcitabine and cisplatin, has missed its primary end point.

A phase 1a/1b, first-in-human study of the novel immunotherapy agent, AB248, has given the agent to its first patient with locally advanced or metastatic solid tumors.

Results from the phase 2 Talem trial, presented at the 2023 Gastrointestinal Cancers Symposium, showed the promising signs of efficacy, anti-tumor activity, and tolerable adverse events when combining blank-microsphere transarterial chemoembolization with lenvatinib and sequential microwave ablation for patients with HCC.

Favorable safety and efficacy data were seen with envafolimab, lenvatinib and transarterial chemoembolization in patients with unresectable hepatocellular carcinoma.

Karen L. Reckamp, MD, MS, discusses findings from the phase 2 Lung-MAP substudy S1800A of pembrolizumab and ramucirumab in patients with stage IV, previously-treated non–small cell lung cancer.

Phase 2 study shows ponatinib and blinatumomab to represent a promising chemotherapy-free, hematopoietic stem cell transplant–sparing treatment for patients with Philadelphia chromosome–positive acute lymphocytic leukemia.

Gayathri Ravi, MD, discusses the role of minimal residual disease testing in patients with newly diagnosed multiple myeloma.

Recent updates to clinical care for patients with ER-positive disease include the emergence of breast cancer subtypes, oral selective estrogen receptor degraders, and other oral targeted therapies.

CheckMate-649 study findings continue to support frontline nivolumab and chemotherapy for patients with advanced gastric, gastroesophageal junction cancer, and esophageal adenocarcinoma.

New findings from the phase 2 INFINITY trial shows promise for tremelimumab and durvalumab in patients with gastric/GEJ adenocarinoma.

LNS8801 has proven to be safe, well-tolerated, and demonstrated clinical benefit in patients with advanced cancers. Now, the FDA has granted the agent orphan drug designation for metastatic cutaneous melanoma.

Zanubrutinib has been granted FDA approval for the treatment of patients with chronic lymphocytic leukemia or small lymphocytic lymphoma.

Findings presented at the 2022 Gastrointestinal Cancers Symposium warrant the need for new treatments that attack HER2-low advanced gastric cancer.